
    
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. All patients
      self-administer daily subcutaneous injections of human parathyroid hormone (1-34) or placebo
      for a period of 2.5 years.

      Patients are followed regularly for unacceptable toxicities.

      Completion date provided represents the completion date of the grant per OOPD records
    
  